These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 15302140

  • 1. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.
    Jacob JR, Korba BE, Cote PJ, Toshkov I, Delaney WE, Gerin JL, Tennant BC.
    Antiviral Res; 2004 Aug; 63(2):115-21. PubMed ID: 15302140
    [Abstract] [Full Text] [Related]

  • 2. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.
    Cullen JM, Li DH, Brown C, Eisenberg EJ, Cundy KC, Wolfe J, Toole J, Gibbs C.
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2740-5. PubMed ID: 11557463
    [Abstract] [Full Text] [Related]

  • 3. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.
    Tatti KM, Korba BE, Stang HL, Peek S, Gerin JL, Tennant BC, Schinazi RF.
    Antiviral Res; 2002 Jul; 55(1):141-50. PubMed ID: 12076758
    [Abstract] [Full Text] [Related]

  • 4. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
    Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC.
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3617-32. PubMed ID: 18676881
    [Abstract] [Full Text] [Related]

  • 5. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
    Menne S, Cote PJ, Korba BE, Butler SD, George AL, Tochkov IA, Delaney WE, Xiong S, Gerin JL, Tennant BC.
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2720-8. PubMed ID: 15980342
    [Abstract] [Full Text] [Related]

  • 6. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL, Takkenberg RB, Weegink CJ, Rebers SP, Menting S, Reesink HW, Schinkel J, Molenkamp R.
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [Abstract] [Full Text] [Related]

  • 7. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F, Kumada H, Nakamura H.
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [Abstract] [Full Text] [Related]

  • 8. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    Liu CJ, Kao JH, Chen PJ, Chen TC, Lin FY, Lai MY, Chen DS.
    J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
    [Abstract] [Full Text] [Related]

  • 9. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 10. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H.
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [Abstract] [Full Text] [Related]

  • 11. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
    Ohkawa K, Takehara T, Kato M, Kanada A, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
    [Abstract] [Full Text] [Related]

  • 12. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H.
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [Abstract] [Full Text] [Related]

  • 13. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD.
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [Abstract] [Full Text] [Related]

  • 14. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
    Mihm U, Gärtner BC, Faust D, Hofmann WP, Sarrazin C, Zeuzem S, Herrmann E.
    J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
    [Abstract] [Full Text] [Related]

  • 15. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
    Scotto G, Palumbo E, Fazio V, Tartaglia A, Saracino A, Angarano G.
    New Microbiol; 2005 Jul; 28(3):193-7. PubMed ID: 16240690
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.